Kanya Rajangam
2023 - Senti Biosciences
In 2023, Kanya Rajangam earned a total compensation of $858.8K as President, Head of Research and Development and Chief Medical Officer at Senti Biosciences, a 2% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $173,531 |
|---|---|
| Option Awards | $168,779 |
| Salary | $516,460 |
| Total | $858,770 |
Rajangam received $516.5K in salary, accounting for 60% of the total pay in 2023.
Rajangam also received $173.5K in non-equity incentive plan and $168.8K in option awards.
Rankings
In 2023, Kanya Rajangam's compensation ranked 1,385th out of 3,006 executives tracked by ExecPay. In other words, Rajangam earned more than 53.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,385 out of 3,006 | 54th |
Division Manufacturing | 826 out of 1,650 | 50th |
Major group Chemicals And Allied Products | 544 out of 918 | 41st |
Industry group Drugs | 531 out of 881 | 40th |
Industry Biological Products, Except Diagnostic Substances | 150 out of 213 | 30th |
Source: SEC filing on January 27, 2025.
Rajangam's colleagues
We found one more compensation record of an executive who worked with Kanya Rajangam at Senti Biosciences in 2023.
2023
Timothy Lu
Senti Biosciences